Name Dean Ho | Role Professor | |
 | ||
Education University of California, Los Angeles Nominations RUSNANOPRIZE for Nanomaterials and Surface Modification | ||
Nanotech today nano engineered medicine dean ho pt 1
Dean Ho is a Professor in the Division of Oral Biology and Medicine and Division of Advanced Prosthodontics, Biomaterials, and Hospital Dentistry, as well as Co-Director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry. He is also a Professor of Bioengineering at the UCLA School of Engineering and Applied Science, where he directs Project NDX, a global effort to bring nanodiamond-modified therapies and personalized medicine technology platforms to the clinic. He is also a member of the Jonsson Comprehensive Cancer Center and California NanoSystems Institute. He was previously an Associate Professor in the Departments of Biomedical Engineering and Mechanical Engineering in the Robert R. McCormick School of Engineering and Applied Science, and Full Member of the Robert H. Lurie Comprehensive Cancer Center at the Feinberg School of Medicine of Northwestern University, Illinois, United States.
Contents
- Nanotech today nano engineered medicine dean ho pt 1
- Nanotech today nano engineered medicine dean ho pt 2
- Research
- References
Nanotech today nano engineered medicine dean ho pt 2
Research
Dr. Ho's research has covered emerging areas of nanomedicine and nanodiamond-based drug delivery. Dr. Ho and his colleagues were the first to develop nanodiamond platforms for cancer therapy and wound healing, among other areas. Dr. Ho and colleagues were the first to demonstrate the translational potential of nanodiamonds as chemotherapeutic delivery agents, specifically towards the treatment of drug-resistant cancers in vivo. This work was published as the Cover Article of the March 9 issue of the journal Science Translational Medicine. He has also developed nanodiamond-functionalized biomaterials for wound healing, anti-infection, and other clinical applications.
Dr. Ho is also known for his work in the area of personalized and precision medicine. His team has partnered with leading bioengineers and clinicians to harness a powerful technology platform named Phenotypic Personalized Medicine (PPM) to optimize combination therapy. PPM has been applied both as a drug development platform, realizing best-in-class medicines for population-wide administration, as well as the unprecedented ability to actionably personalize treatment for the entire duration of care on a patient-specific basis. Dr. Ho's extensive research achievements have garnered news coverage in The Economist, Forbes, Nature (journal), CNN, NPR, as well as The Washington Post. He was also featured in the National Geographic Channel program, Known Universe. Most recently, the PPM technology platform was featured by FuturizeX, a partnership between the X PRIZE Foundation and UCLA. The PPM platform was also featured globally at InnovFest Unbound, and recognized as a finalist for the SLAS Innovation Award.
Previously, Dr. Ho served the Editor-in-Chief of the Journal of Laboratory Automation, now known as SLAS Technology. He also served as the President of the Board of Directors of the Society for Laboratory Automation and Screening which is a 20,000+ member drug development and life sciences technology organization. Dr. Ho is a recipient of the National Science Foundation CAREER Award, Wallace H. Coulter Foundation Translational Research Award, V Foundation for Cancer Research V Scholar Award, John G. Bollinger Outstanding Young Manufacturing Engineering Award of the Society of Manufacturing Engineers, UCLA School of Engineering and Applied Science Distinguished Young Alumnus Award, IADR William J. Gies Award, and IADR Young Investigator Award. He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and the Society for Laboratory Automation and Screening (SLAS). He was also named to the 2016 Power List of The Pathologist Magazine.